Journal News

Do ribosomal traffic jams cause Huntington’s disease?

Uzma Rentia
By Uzma Rentia
Sept. 5, 2024

Huntington's disease, or HD, a genetic disorder that affects about one in every 10,000 people in the U.S., is inherited in an autosomally dominant manner, meaning that a person with the condition has a 50% chance of passing it on to their child. HD kills important neurons in the brain, causing uncontrollable movements and cognitive and psychiatric changes.

While scientists have long known that HD is caused by a cytosine–adenine–guanine trinucleotide repeat in the Huntingtin gene contained on chromosome 4, they are still studying the biological mechanisms that guide the disease process. In particular, researchers have implicated mitochondrial dysfunction in the pathophysiology of HD, and it is an ongoing focus of study.

Investigators at the Wertheim University of Florida Scripps Research Institute recently used novel techniques to examine mRNA translation within the mitochondria of mice genetically altered to have HD. They found that ribosomes — particles responsible for creating proteins from instructions encoded in mRNA — get clustered and jammed on mitochondrial mRNA transcripts. The team published these new findings, in the journal Molecular & Cellular Proteomics.

Srinivasa Subramaniam, an associate professor at Wertheim UF Scripps, was the lead author on the study. “Imagine going from Baltimore to Washington, D.C., and there are too many cars, and they are all jammed up,” he said. “Just because there are many cars does not mean they are all reaching their destination.

“So, what does that mean for the patient? That means that the patient may have difficulty translating their mitochondrial protein. And that may lead to problems in the assembly of these complexes, which may lead to problems in mitochondrial function.”

Mitochondrial protein synthesis is diminished in Huntington’s disease cells. These mouse striatal cells have a normal genotype (left) or are heterozygous (center) or homozygous (right) for a Huntington’s disease mutation. Puromycin uptake is shown in green and represents the cellular protein translation rate. Nuclei are shown in blue.
MCP
Mitochondrial protein synthesis is diminished in Huntington’s disease cells. These mouse striatal cells have a normal genotype (left) or are heterozygous (center) or homozygous (right) for a Huntington’s disease mutation. Puromycin uptake is shown in green and represents the cellular protein translation rate. Nuclei are shown in blue.

This project followed from Subramaniam’s previous work, which demonstrated high expression of fragile X messenger ribonucleoprotein, or FMRP, a protein that blocks ribosomes in HD. Consequently, he was curious to see the spatial distribution of ribosomes on mitochondrial mRNA, so Subramaniam turned to a technique called Ribo-Seq, which provides a snapshot of the location and density of ribosomes on a given mRNA transcript. He had no experience with the technique and immediately faced challenges.

“I am a biochemist by training,” Subramaniam said. “So I needed to sit and write hundreds of emails like ‘Can you help me?’ all over the world.”

He connected with collaborators in France and Ireland and took on a postdoc with Ribo-Seq experience. Almost four years later, Subramaniam and his lab published the results of their work. And with these results come new questions.

Previous research has shown that deleting the FMRP protein can prevent some cognitive deficits observed in HD. Subramaniam wants to investigate how modulating the expression of FMRP can affect the spatial distribution of ribosomes on mRNA transcripts. He also wants to see how communication between the cytoplasm and mitochondria contributes to what he likens to a "traffic jam."   He hypothesizes that the cytoplasm inhibits proper functioning of mitochondrial mRNA, creating confusion.

“Imagine if you are traveling through a tunnel, and you close that tunnel,” he said. “Who puts on that brake? Who triggered that pathway? What is the signal that makes this traffic jam? That is what I want to know in more detail at the molecular level.”

He hopes this work has practical applications as well.

“How can we use small-molecule screening to reverse this phenotype?” he said. “My goal is to identify the mechanisms and then leverage potential therapeutics.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Uzma Rentia
Uzma Rentia

Uzma Rentia is a third-year medical student at George Washington University in Washington, D.C., who is also enrolled in the University of California, San Diego Science Writing Certificate Program. She is an ASBMB Today volunteer contributor.

Related articles

From the journals: JLR
Swarnali Roy
From the journals: MCP
Krishnakoli Adhikary
From the journals: MCP
Naushin Raheema
From the journals: MCP
Ankita Arora

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

From the journals: JLR
Journal News

From the journals: JLR

Dec. 13, 2024

Fixation method to quantify brain metabolites. Belly fat and liver disease crosstalk. Stopping heart diseases in schizophrenic patients. Read about the recent JLR papers on these topics.

Does a protein hold the key to Alzheimer’s?
Journal News

Does a protein hold the key to Alzheimer’s?

Dec. 10, 2024

Researchers in Maryland and Massachusetts team up to study how SORL1 promotes tau trafficking and seeding in cells that leads to the neurodegenerative disorder.

Cracking the recipe for perfect plant-based eggs
News

Cracking the recipe for perfect plant-based eggs

Dec. 8, 2024

It involves finding just the right proteins. With new ingredients and processes, the next generation of substitutes will be not just more egg-like, but potentially more nutritious.

MSU researchers leverage cryo-EM for decades-in-the-making breakthrough
News

MSU researchers leverage cryo-EM for decades-in-the-making breakthrough

Dec. 7, 2024

Lee Kroos and Ben Orlando have reported the first high-resolution experimentally determined structures of the intramembrane protease SpolVFB.

From the Journals: MCP
Journal News

From the Journals: MCP

Dec. 6, 2024

Rapid and precise SARS-CoV-2 detection using mass spec. Mapping brain changes from drug addiction. Decoding plant osmotic stress response. Read about recent MCP papers on these topics.

What seems dead may not be dead
Award

What seems dead may not be dead

Dec. 4, 2024

Vincent Tagliabracci will receive the Earl and Thressa Stadtman Distinguished Scientist Award at the ASBMB Annual Meeting, April 12–15 in Chicago.